XPH News and Press, SPDR S&P Pharmaceuticals From 04/22/21

Rep. Frank Pallone, Jr. (D-N.J.) reintroduced H.R. 3, legislation that would allow the federal government to negotiate prescription drug prices.The bill would cap seniors' out-of-pocket costs on prescription drugs to $2000/year, require drugmakers to issue rebates to the federal government if...

This has been a long, long boom in the amount of money that's flowed into this sector, and I don't think I've ever seen anything like it in my own career. This has been VC money going into early-stage startups, it's been IPOs, it's been follow-on financing of already public companies....

When influential investors make decisions to buy and sell securities, they normally want to keep it quiet.  However, if we pay close attention we can see what is going on, and make good decisions.. The Spdr S&p Pharmaceuticals (NYSE: XPH) report below can help you understand ho...

The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively resilient throughout the pandemic, we expect a full recovery in the latter half of thi...

Just over one year after COVID-19 disrupted our lives, we are now getting to the point where multiple vaccine options are nearly ubiquitous for those in the United States. Per the CDC, as of April 12, 36% of the entire US population has received at least one vaccine, and 79% of those ...

Often, the action in a stock is based on investors perceptions, but it can be a circular event.  Not only is the price action representative of perception, but it can influence perception too.  In the case of Spdr S&p Pharmaceuticals (NYSE: XPH) we can see this in the char...

In our opinion, telehealth will remain the leading segment of the internet healthcare market as the market shifts away from in-person medical visits. According to Apple CEO Tim Cook, “I believe, if you zoom out into the future, and you look back, and you ask the question, ...

Traditionally Wall Street has used fundamental analysis to make investment decisions in stocks like Spdr S&p Pharmaceuticals (NYSE: XPH) but sometimes the most revealing aspect of the fundamental health of a company can be found through an observation of its price action.  Pric...

SPDR S&P Pharmaceuticals ETF (XPH) - $0.0725.30-Day SEC Yield of 0.41% as of Mar 19.Payable Mar 25; for shareholders of record Mar 23; ex-div Mar 22. For further details see: SPDR S&P Pharmaceuticals ETF declares quarterly distribution of $0.0725

Investors in Spdr S&p Pharmaceuticals (NYSE: XPH) like to make good decisions, that means they like to buy and sell at the right times, and to do that the best tools involve charts, pivot points, and the technical data.  Below, we have provided a snapshot for XPH that reve...